Liposomal Daunorubicin treatment increases quality of life in HIV-associated Kaposi’s Sarcoma

1994 ◽  
pp. 707-709
Author(s):  
C. A. Presant ◽  
M. Scolaro ◽  
P. Kennedy ◽  
D. W. Blayney ◽  
B. Flanagan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Liposomal Daunorubicin

scholarly journals Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: Results of a randomized quality of life focused clinical trial

2004 ◽  
Vol 113 (4) ◽  
pp. 632-639 ◽  
Author(s):  
Charles L.M. Olweny ◽  
Margaret Borok ◽  
Ivy Gudza ◽  
Jennifer Clinch ◽  
Mary Cheang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

scholarly journals Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi’s Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya

2018 ◽  
pp. 1-9 ◽  
Author(s):  
Naftali W. Busakhala ◽  
Paul J. Waako ◽  
Matthew Robert Strother ◽  
Alfred Kipyegon Keter ◽  
Gabriel Kimutai Kigen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Antiretroviral Therapy ◽  
Adverse Events ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Herpès Virus

Purpose Kaposi’s sarcoma (KS) is a spindle cell tumor resulting from growth dysregulation in the setting of infection with human herpes virus-8 (also called KS herpes virus). Advanced KS is characterized by poor responses to antiretroviral therapy and some of the chemotherapy readily accessible to patients in low-resource areas. Gemcitabine induced partial and complete regression of AIDS-associated KS (AIDS-KS) in 11 of 24 patients in a pilot study. The current study compares the antimetabolite gemcitabine with the standard care bleomycin and vincristine (BV) in the treatment of chemotherapy-naïve patients with AIDS-KS in a resource-limited setting. Patients and Methods Patients with persistent or progressive KS despite treatment with combined antiretroviral therapy were randomly assigned to receive gemcitabine 1,000 mg/m2 or bleomycin 15 IU/ m2 and vincristine 1.4 mg/m2 given twice weekly. The main end point was objective response by bidirectional measurement, adverse events, and quality of life after three cycles of chemotherapy. Results Of 70 participants enrolled, 36 received gemcitabine and 34 received BV. Complete response was achieved in 12 patients (33.3%) in the gemcitabine arm and six (17.6%) in the BV arm ( P = .175). The partial response rate was 52.8% (n = 19) in the gemcitabine arm and 58.8% (n = 20) in the BV arm. Both study arms reported similar neurologic and hematologic adverse events; there was statistically significant baseline to post-treatment improvement in health-related quality-of-life scores. Conclusion The results of this randomized, phase IIA trial demonstrate gemcitabine activity in chemotherapy-naïve patients with AIDS-KS, on the basis of response rates, adverse events, and health-related quality-of-life scores.

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi’s Sarcoma: An AIDS Clinical Trials Group Clinical Study

2002 ◽  
Vol 20 (15) ◽  
pp. 3236-3241 ◽  
Author(s):  
Scott R. Evans ◽  
Susan E. Krown ◽  
Marcia A. Testa ◽  
Timothy P. Cooley ◽  
Jamie H. Von Roenn
Keyword(s):  
Quality Of Life ◽  
Partial Response ◽  
Phase Ii ◽  
Kaposi's Sarcoma ◽  
Low Dose ◽  
Kaposi’S Sarcoma ◽  
Oral Etoposide ◽  
Patient Reported ◽  
Dose Oral

PURPOSE: Liposomal anthracyclines and paclitaxel are considered the best available cytotoxic therapies for Kaposi’s sarcoma (KS), but relapse is common. To identify new interventions for relapsed or progressive KS, a phase II study of low-dose etoposide to assess its toxicity and efficacy was conducted. PATIENTS AND METHODS: Thirty-six patients with high-risk KS were treated with oral etoposide 50 mg/d for 7 consecutive days of every 2-week cycle. All patients’ disease had relapsed or progressed after prior combination chemotherapy or anthracycline therapy. For patients without a complete or partial response after two cycles of therapy and no toxicity greater than grade 2, the dose of etoposide was escalated to 100 mg/d orally on days 1 to 7 of each 14-day cycle. Treatment-related and disease-specific quality of life was evaluated using patient reports on the General Health Self-Assessment Form and a KS-specific measure. RESULTS: One patient achieved a complete response, 12 patients had a partial response (overall response rate, 36.1%), and stable disease was observed in 12 patients (33.3%). Tumor responses were seen in all disease sites. Fourteen patients had their dose escalated, of whom five responded. The median time to response was 17.7 weeks; the median duration of response was 25 weeks. The most frequent hematologic abnormality was neutropenia, which was grade 4 in seven patients and grade 3 in six. Opportunistic infections occurred in eight patients during the treatment period. Both response to treatment and toxicity influenced patient-reported quality of life. CONCLUSION: We conclude that low-dose oral etoposide at a dose of 50 mg/d is safe and effective for the treatment of refractory or progressed AIDS-related KS and has an overall positive effect on the quality of life of responding patients.

Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.

1998 ◽  
Vol 16 (10) ◽  
pp. 3369-3374 ◽  
Author(s):  
A Tulpule ◽  
R C Yung ◽  
J Wernz ◽  
B M Espina ◽  
A Myers ◽  
...  
Keyword(s):  
Kaposi's Sarcoma ◽  
Pulmonary Function Tests ◽  
Blood Gases ◽  
Kaposi’S Sarcoma ◽  
Liposomal Daunorubicin ◽  
Partial Resolution ◽  
Arterial Blood ◽  
Male Patients ◽  
The Mean ◽  
Cd4 Lymphocyte

PURPOSE Kaposi's sarcoma (KS) is the most common tumor in patients with AIDS and can be fatal in patients with lung involvement. Systemic chemotherapy is the most effective treatment for pulmonary KS. We thus conducted this study to determine the efficacy of liposomal daunorubicin in the treatment of patients with pulmonary KS. METHODS Patients with biopsy-proven, symptomatic pulmonary KS were accrued. Liposomal daunorubicin was given at a dose of 60 mg/m2 intravenously every 2 weeks. Response was monitored by chest radiographs, pulmonary function tests, arterial blood gases, and grading of pulmonary symptoms. RESULTS Fifty-three male patients were accrued. The median CD4+ lymphocyte count was 13/microL (range, 0 to 200); 70% reported a prior AIDS-defining opportunistic infection. All patients were symptomatic, with cough reported in all patients, shortness of breath in 94%, and hemoptysis in 55%. The mean study entry diffusing capacity of carbon monoxide (DLCO) was 58.5% (percent of predicted). The median dose of liposomal daunorubicin delivered was 360 mg/m2 (range, 60 to 1,380). More than 75% of patients had complete or partial resolution of baseline pulmonary symptoms. Complete or partial improvement in DLCO was observed in 22%; complete or partial resolution of radiographic abnormalities was reported in 32%. The most common treatment-related toxicity was neutropenia, which occurred in 85%. There were no instances of cardiac toxicity observed, even at high cumulative doses. CONCLUSION Liposomal daunorubicin at 60 mg/m2 is safe and active in patients with pulmonary KS. Trials combining liposomal daunorubicin with other active agents in KS should be considered.

scholarly journals Computational investigation of marine bioactive compounds reveals frigocyclinone as a potent inhibitor of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) targets

2019 ◽  
Vol 12 (3) ◽  
pp. 1289-1302
Author(s):  
Nirmaladevi Ponnusamy ◽  
Rajasree Odumpatta ◽  
Pavithra Damodharan ◽  
Mohanapriya Arumugam
Keyword(s):  
Bioactive Compounds ◽  
Drug Targets ◽  
Kaposi's Sarcoma ◽  
Protein Structures ◽  
In Silico Analysis ◽  
Kaposi’S Sarcoma ◽  
The Stability ◽  
Salicylihalamide A ◽  
Experimental Structure

In the present study, in silico analysis was employed to identify the action of marine bioactive compounds against KSHV targets. Virulence factor analysis of KSHV from literature review, three proteins LANA1, vIRF3/LANA2 and PF-8 were identified as putative drug targets. The quality of protein structures play a significant role in the experimental structure validation and prediction, where the predicted structures may contain considerable errors was checked by SAVES v5.0 servers. By virtual screening four potential bioactive compounds Ascorbic acid, Salicylihalamide A, Salicylihalamide B and Frigocyclinone were predicted. One of the potential compounds of Frigocyclinone has acting against KSHV proteins. Hence, determined as the good lead molecule against KSHV. Molecular dynamic simulation studies revealed the stability of LANA1- Frigocyclinone complex and it could be a futuristic perspective chemical compound for Kaposi’s sarcoma.

scholarly journals Trends in Kaposi’s Sarcoma in Miami Beach from 1987 to 2007

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10
Author(s):  
Simon B. Zeichner ◽  
Ana L. Ruiz ◽  
Gabriel P. Suciu ◽  
Rachel Lerner Zeichner ◽  
Estelamari Rodriguez
Keyword(s):  
Kaposi's Sarcoma ◽  
Medical Center ◽  
Kaposi’S Sarcoma ◽  
Vascular Tumor ◽  
Low Grade ◽  
Term Survival ◽  
Distant Disease ◽  
Human Herpes Virus 8

Purpose. Kaposi’s sarcoma (KS) is a rare low-grade vascular tumor associated with the human herpes virus 8. By analyzing the epidemiology, staging, and treatment of KS, we hoped to improve the quality of care at our institution. Methods. Review of the Mount Sinai Medical Center tumor registry database in Miami Beach, FL, USA, identified 143 cases of KS between January 1, 1987 and December 31, 2007. Results. The majority of patients were non-Hispanic whites, non smoking males diagnosed between 1987 and 1996. Most of the patients were HIV positive, with an equal percentage diagnosed with local or distant disease. Most patients received no chemotherapy or radiation. There were no significant differences in patient survival based on sex, HIV status, or radiation received. There was a trend toward improved survival among older patients who smoked, received no chemotherapy, and had localized stage at diagnosis. Multivariate analysis revealed that non-Hispanic whites had a significant worse survival than Hispanic whites (HR = 0.55, 95% CI (0.33, 0.90), ). Patients diagnosed between 1987 and 1996 had a worse survival than those between 1997 and 2007 (HR = 0.33 (95% CI 0.19, 0.55), ). Conclusion. This large retrospective study provides further insight into KS. Ethnicity and date of diagnosis are important predictors of long-term survival.

Sign in / Sign up

Export Citation Format

Share Document